Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Novo Nordisk A/S's quarterly P/E stands at 0.8x, down 68.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 49.8% YoY to 1.1x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 13.02 | 0.84 | 2.11 | 3.08 | 2.90 | 2.66 | 3.40 | 4.86 | 7.95 | 5.65 | 5.27 | 4.55 | 4.68 |
| — | -68.3% | -38.0% | -36.6% | -63.6% | -53.0% | -35.5% | +7.0% | +69.7% | +24.7% | -6.3% | +16.1% | -1.5% | |
| P/S Ratio | 4.31 | 0.42 | 0.71 | 0.82 | 1.00 | 0.99 | 1.12 | 1.86 | 2.34 | 2.20 | 1.76 | 1.74 | 1.68 |
| — | -57.3% | -36.1% | -55.8% | -57.4% | -55.0% | -36.3% | +7.2% | +39.6% | +30.5% | +10.5% | +40.1% | +9.2% | |
| P/B Ratio | 6.87 | 0.81 | 1.17 | 1.45 | 1.83 | 2.23 | 2.67 | 4.41 | 39.42 | 5.80 | 4.35 | 30.92 | 27.48 |
| — | -63.9% | -56.4% | -67.0% | -95.4% | -61.6% | -38.5% | -85.7% | +43.4% | -81.2% | +18.6% | +38.2% | +13.4% | |
| P/FCF | 45.95 | 3.39 | — | 2.01 | 3.13 | 7.72 | — | 4.24 | 4.28 | 27.05 | — | 3.36 | 4.23 |
| — | -56.0% | — | -52.6% | -26.8% | -71.5% | — | +25.9% | +1.1% | +653.6% | — | +19.1% | +42.6% | |
| EV / EBITDA | 9.60 | 1.14 | 2.22 | 2.51 | 2.53 | 2.28 | 2.81 | 3.69 | 4.59 | 4.28 | 4.00 | 3.46 | 3.50 |
| — | -49.8% | -21.0% | -31.9% | -44.8% | -46.7% | -29.8% | +6.6% | +31.0% | +26.8% | -8.3% | +36.4% | +10.4% | |
| EV / EBIT | 11.25 | 1.10 | 2.61 | 3.33 | 2.50 | 2.30 | 2.90 | 3.77 | 5.93 | 4.37 | 4.66 | 3.37 | 3.72 |
| — | -52.2% | -10.0% | -11.6% | -57.8% | -47.4% | -37.9% | +11.9% | +59.5% | +25.4% | -51.6% | +30.0% | +17.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Novo Nordisk A/S's operating margin was 61.6% in Q1 2026, up 21.5 pp QoQ and up 11.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 44.2% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.0% | 86.0% | 80.9% | 76.1% | 83.3% | 83.5% | 84.8% | 84.1% | 84.9% | 84.8% | 84.8% | 83.5% | 85.5% |
| — | +2.9% | -4.6% | -9.5% | -1.9% | -1.6% | +0.0% | +0.8% | -0.7% | +0.2% | +2.4% | -0.9% | +0.3% | |
| Operating Margin | 41.3% | 61.6% | 40.1% | 31.6% | 43.5% | 49.7% | 42.9% | 47.4% | 38.1% | 48.7% | 40.6% | 45.8% | 44.0% |
| — | +24.0% | -6.5% | -33.4% | +14.2% | +1.9% | +5.5% | +3.5% | -13.4% | +4.0% | +14.4% | +3.4% | -1.3% | |
| Net Margin | 33.1% | 50.2% | 34.0% | 26.7% | 34.5% | 37.2% | 32.9% | 38.3% | 29.5% | 38.9% | 33.3% | 38.3% | 35.8% |
| — | +34.9% | +3.1% | -30.3% | +17.1% | -4.4% | -1.2% | +0.0% | -17.7% | +4.7% | +18.0% | +21.1% | +10.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 60.7% | 24.5% | 14.8% | 11.8% | 17.3% | 20.6% | 21.4% | 39.9% | 34.8% | 24.7% | 36.7% | 169.9% | 156.0% |
| — | +18.8% | -30.9% | -70.4% | -50.4% | -16.7% | -41.7% | -76.5% | -77.7% | -40.6% | +26.3% | +21.3% | +19.6% | |
| ROA | 20.3% | 8.8% | 5.1% | 4.0% | 5.5% | 6.1% | 6.5% | 12.1% | 11.4% | 8.3% | 12.3% | 53.7% | 50.1% |
| — | +44.9% | -22.1% | -66.8% | -52.1% | -26.6% | -46.8% | -77.4% | -77.2% | -41.9% | +23.6% | +17.0% | +13.3% | |
| ROIC | 36.2% | 14.3% | 8.9% | 7.3% | 10.7% | 13.0% | 15.7% | 37.0% | 28.5% | 20.0% | 30.4% | 152.0% | 132.4% |
| — | +10.1% | -43.6% | -80.3% | -62.4% | -35.2% | -48.4% | -75.7% | -78.5% | -41.4% | +26.4% | +3.5% | +8.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Novo Nordisk A/S's Debt/EBITDA ratio is 2.3x, down from 3.5x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 6.6% YoY to 0.79x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 0.72 | 0.67 | 0.60 | 0.59 | 0.86 | 0.72 | 0.47 | 0.51 | 0.27 | 0.25 | 0.29 | 0.28 |
| — | -15.9% | -5.8% | +26.0% | +16.5% | +214.8% | +182.7% | +65.6% | +78.5% | -14.8% | -17.9% | -15.7% | -16.8% | |
| Debt / EBITDA | 0.88 | 2.32 | 3.51 | 3.22 | 2.59 | 2.79 | 2.45 | 1.58 | 0.24 | 0.77 | 0.91 | 0.13 | 0.14 |
| — | -16.8% | +43.2% | +103.3% | +999.8% | +259.6% | +170.1% | +1137.4% | +63.2% | +456.3% | -35.5% | -16.9% | -19.1% | |
| Current Ratio | 0.80 | 0.79 | 0.80 | 0.78 | 0.78 | 0.74 | 0.74 | 0.94 | 0.94 | 0.70 | 0.82 | 0.82 | 0.88 |
| — | +6.6% | +8.1% | -17.1% | -17.0% | +5.1% | -10.1% | +13.7% | +7.6% | -18.6% | -8.0% | -10.2% | -6.5% | |
| Quick Ratio | 0.57 | 0.56 | 0.57 | 0.57 | 0.56 | 0.56 | 0.55 | 0.75 | 0.75 | 0.50 | 0.64 | 0.65 | 0.70 |
| — | +0.4% | +3.2% | -24.0% | -24.9% | +11.4% | -13.2% | +15.6% | +7.4% | -25.3% | -8.3% | -11.6% | -5.6% | |
| Interest Coverage | 32.03 | 18.77 | — | — | 7.82 | 8.15 | 7.98 | 42.88 | 17.22 | 16.39 | 27.86 | 13.94 | 87.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into NVO consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVO stock.
Novo Nordisk A/S's current P/E is 13.0x. The average P/E over the last 4 quarters is 2.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Novo Nordisk A/S's current operating margin is 41.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Novo Nordisk A/S's business trajectory between earnings reports.